Timing and Completeness of Trial Results Posted at ClinicalTrials.gov and Published in Journals
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The US Food and Drug Administration Amendments Act requires results from clinical trials of Food and Drug Administration-approved drugs to be posted at ClinicalTrials.gov within 1 y after trial completion. We compared the timing and completeness of results of drug trials posted at ClinicalTrials.gov and published in journals. METHODS AND FINDINGS: We searched ClinicalTrials.gov on March 27, 2012, for randomized controlled trials of drugs with posted results. For a random sample of these trials, we searched PubMed for corresponding publications. Data were extracted independently from ClinicalTrials.gov and from the published articles for trials with results both posted and published. We assessed the time to first public posting or publishing of results and compared the completeness of results posted at ClinicalTrials.gov versus published in journal articles. Completeness was defined as the reporting of all key elements, according to three experts, for the flow of participants, efficacy results, adverse events, and serious adverse events (e.g., for adverse events, reporting of the number of adverse events per arm, without restriction to statistically significant differences between arms for all randomized patients or for those who received at least one treatment dose). From the 600 trials with results posted at ClinicalTrials.gov, we randomly sampled 50% (n = 297) had no corresponding published article. For trials with both posted and published results (n = 202), the median time between primary completion date and first results publicly posted was 19 mo (first quartile = 14, third quartile = 30 mo), and the median time between primary completion date and journal publication was 21 mo (first quartile = 14, third quartile = 28 mo). Reporting was significantly more complete at ClinicalTrials.gov than in the published article for the flow of participants (64% versus 48% of trials, p<0.001), efficacy results (79% versus 69%, p = 0.02), adverse events (73% versus 45%, p<0.001), and serious adverse events (99% versus 63%, p<0.001). The main study limitation was that we considered only the publication describing the results for the primary outcomes. CONCLUSIONS: Our results highlight the need to search ClinicalTrials.gov for both unpublished and published trials. Trial results, especially serious adverse events, are more completely reported at ClinicalTrials.gov than in the published article.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Clinical trial registries are an important source of information for tracking clinical trials from their inception through to their reporting, and have been used to measure publication bias and outcome reporting bias.”
From Systematic review protocol assessing the processes for linking clinical trial registries and their published results (2016) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 7,226
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group* (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00232 · Cited by 3,824
Publication bias in clinical research
Easterbrook, P. J., Gopalan, R., Berlin, J. A., & Matthews, D. R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90201-y · Cited by 3,109
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Avoidable waste in the production and reporting of research evidence
Chalmers, I., & Glasziou, P. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60329-9 · Cited by 2,208
Chan, A.-W., Hróbjartsson, A., Haahr, M. T., Gøtzsche, P. C., & Altman, D. G. (2004) · JAMA · doi:10.1001/jama.291.20.2457 · Cited by 1,845
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Ioannidis, J. P. A., Evans, S. J. W., Gøtzsche, P. C., O'Neill, R. T., Altman, D. G., Schulz, K., Moher, D., & for the CONSORT Group* (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00009 · Cited by 1,593 · cited 1×
“The reporting of adverse events observed at a certain frequency or threshold rate has been previously outlined as poor reporting practice [37].”
Backgroundmeta-analysis bias in location and selection of studies
Egger, M., & Smith, G. D. (1998) · BMJ · doi:10.1136/bmj.316.7124.61 · Cited by 1,374
Kirkham, J. J., Dwan, K. M., Altman, D. G., Gamble, C., Dodd, S., Smyth, R., & Williamson, P. R. (2010) · BMJ · doi:10.1136/bmj.c365 · Cited by 1,133
Publication bias in clinical trials due to statistical significance or direction of trial results
Hopewell, S., Loudon, K., Clarke, M. J., Oxman, A. D., & Dickersin, K. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000006.pub3 · Cited by 898
The ClinicalTrials.gov Results Database — Update and Key Issues
Zarin, D. A., Tse, T., Williams, R. J., Califf, R. M., & Ide, N. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmsa1012065 · Cited by 838 · cited 1×
“gov is designed to complement, not replace, journal publication [28].”
BackgroundIoannidis, J. P. A. (1998) · JAMA · doi:10.1001/jama.279.4.281 · Cited by 632 · cited 1×
“This waste of research can occur at different stages: (1) failure to publish results of some studies, particularly those with negative results, ‘‘publication bias’’ [6–8]; (2) delay in publishing results of negative studies [9], ‘‘timelag bias’’ [10]; and (3) failure to publish complete results for all prespecified ou…”
BackgroundTurner, L., Shamseer, L., Altman, D. G., Schulz, K. F., & Moher, D. (2012) · Systematic Reviews · doi:10.1186/2046-4053-1-60 · Cited by 628
Chan, A.-W., & Altman, D. G. (2005) · BMJ · doi:10.1136/bmj.38356.424606.8f · Cited by 613
Underreporting Research Is Scientific Misconduct
Chalmers, L. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03440100121018 · Cited by 551
Characteristics of Clinical Trials Registered in ClinicalTrials.gov, 2007-2010
Califf, R. M. (2012) · JAMA · doi:10.1001/jama.2012.3424 · Cited by 516
Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research
Chan, A.-W. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041086 · Cited by 444
Trial Publication after Registration in ClinicalTrials.Gov: A Cross-Sectional Analysis
Ross, J. S., Mulvey, G. K., Hines, E. M., Nissen, S. E., & Krumholz, H. M. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000144 · Cited by 401 · cited 1×
“gov and showed that fewer than half were published [20].”
BackgroundTrial Registration at ClinicalTrials.gov between May and October 2005
Zarin, D. A., Tse, T., & Ide, N. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa053234 · Cited by 291
Prayle, A. P., Hurley, M. N., & Smyth, A. R. (2012) · BMJ · doi:10.1136/bmj.d7373 · Cited by 290
Reporting of Safety Results in Published Reports of Randomized Controlled Trials
(2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.306 · Cited by 287 · cited 1×
“published in 2009 found that 73% of articles published in journals with a high impact factor reported serious adverse events [33].”
BackgroundSelf-citationIssues in the Registration of Clinical Trials
Zarin, D. A., Ide, N. C., Tse, T., Harlan, W. R., West, J. C., & Lindberg, D. A. B. (2007) · JAMA · doi:10.1001/jama.297.19.2112 · Cited by 222
Moving Toward Transparency of Clinical Trials
Zarin, D. A., & Tse, T. (2008) · Science · doi:10.1126/science.1153632 · Cited by 182
Reporting “Basic Results” in ClinicalTrials.gov
Tse, T., Williams, R. J., & Zarin, D. A. (2009) · CHEST Journal · doi:10.1378/chest.08-3022 · Cited by 140
Wieseler, B., Kerekes, M. F., Vervoelgyi, V., McGauran, N., & Kaiser, T. (2012) · BMJ · doi:10.1136/bmj.d8141 · Cited by 129 · cited 1×
“A recent study published in 2012 [22] compared the quality of reporting among registry reports, clinical study reports submitted to regulatory authorities, and journal publications.”
BackgroundHuić, M., Marušić, M., & Marušić, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025258 · Cited by 114 · cited 1×
“gov contained insufficient methodological information for assessing risk of bias [21,38].”
BackgroundUnder-reporting of clinical trials is unethical
Antes, G., & Chalmers, I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12838-3 · Cited by 109
Registering a clinical trial in ClinicalTrials.gov.
Zarin, D., & Keselman, A. (2007) · Chest · doi:10.1378/chest.06-2450 · Cited by 100
Public Availability of Results of Trials Assessing Cancer Drugs in the United States
Nguyen, T.-A.-H., Dechartres, A., Belgherbi, S., & Ravaud, P. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.9577 · Cited by 83
Self-citationUse of Trial Register Information during the Peer Review Process
Mathieu, S., Chan, A.-W., & Ravaud, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059910 · Cited by 71 · cited 1×
“Nevertheless, a more recent study showed that only 34% of reviewers examined information registered in a trial registry [34].”
BackgroundSelf-citationReveiz, L., Chan, A.-W., Krleža-Jerić, K., Granados, C. E., Pinart, M., Etxeandia, I., Rada, D., Martinez, M., Bonfill, X., & Cardona, A. F. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012484 · Cited by 47
Update on Registration of Clinical Trials in ClinicalTrials.gov
Tse, T., Williams, R. J., & Zarin, D. A. (2009) · CHEST Journal · doi:10.1378/chest.09-1219 · Cited by 42
An unfinished trip through uncertainties
Liberati, A. (2004) · BMJ · doi:10.1136/bmj.328.7438.531 · Cited by 35
Research without results: Inadequate public reporting of clinical trial results
Gopal, R. K., Yamashita, T. E., & Prochazka, A. V. (2012) · Contemporary Clinical Trials · doi:10.1016/j.cct.2012.02.001 · Cited by 23
Shamliyan, T. (2010) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s12398 · Cited by 7
Clinical trials registries: towards improved access to therapeutic data.
Keerthi, V., & Ana, A. (2008) · PubMed · Cited by 1
Cited by
Gray literature: An important resource in systematic reviews
Paez, A. (2017) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12266 · Cited by 1,459
Increasing value and reducing waste: addressing inaccessible research
Chan, A.-W., Song, F., Vickers, A., Jefferson, T., Dickersin, K., Gøtzsche, P. C., Krumholz, H. M., Ghersi, D., & van der Worp, H. B. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62296-5 · Cited by 887
Grey literature: An important resource in systematic reviews
Páez, A. (2017) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12265 · Cited by 604
Dealing with the positive publication bias: Why you should really publish your negative results
Mlinarić, A., Horvat, M., & Šupak Smolčić, V. (2017) · Biochemia Medica · doi:10.11613/bm.2017.030201 · Cited by 514
“Clinical trials’ results, especially studies with serious adverse events, often remain unpublished (23).”
BackgroundMedical Student Research: An Integrated Mixed-Methods Systematic Review and Meta-Analysis
Amgad, M., Man Kin Tsui, M., Liptrott, S. J., & Shash, E. (2015) · PLOS ONE · doi:10.1371/journal.pone.0127470 · Cited by 326
“gov had no corresponding journal publication [113].”
Metadata
- Authors
- Riveros, C., Dechartres, A., Perrodeau, E., Haneef, R., Boutron, I., & Ravaud, P.
- Affiliations
- Inserm (FR)
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-12-03
- Volume
- 10
- Issue
- 12
- Pages
- e1001566
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC3849189
- OpenAlex
- W2035759032
- Cited by
- 269
- References
- 40
- Citations by year
- 2026: 8 · 2025: 21 · 2024: 22 · 2023: 17 · 2022: 16 · 2021: 18 · 2020: 19 · 2019: 22 · 2018: 29 · 2017: 27 · 2016: 21 · 2015: 28 · 2014: 17 · 2013: 3
- FWCI
- 25.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Columbia Academic Commons (Columbia University)
- Topics
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Social Sciences › Library and Information Sciences › Academic Publishing and Open Access
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Keywords
- ClinicalTrials.gov, drug trials, clinical trial registration, time to publication, serious adverse events, adverse event reporting, reporting completeness, randomized controlled trials, unpublished trials
- MeSH terms
- Clinical Trials as Topic, Humans, Publishing, Time Factors, United States, Databases, Factual
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.